Cooper Companies Inc
The Cooper Companies, Inc. (COO)
Overview
The Cooper Companies is a global medical device company operating in the health care sector, best known as one of the "big four" makers of soft contact lenses. Headquartered in San Ramon, California (with its women's health division, CooperSurgical, based in Trumbull, Connecticut), the company traces its roots to 1958 and entered the contact lens business in 1972, taking its current corporate form (and name) in 1987. Cooper trades on Nasdaq under COO, employs roughly 15,000 people worldwide, and generates trailing-twelve-month revenue of about $4.2 billion, with a market capitalization in the neighborhood of $13–14 billion. The company operates through two focused divisions — CooperVision (contact lenses) and CooperSurgical (fertility and women's health) — that together make Cooper one of relatively few pure-play medtech companies straddling both vision care and reproductive/women's health.
What They Do & How They Make Money
Cooper makes money by manufacturing and selling recurring-use medical consumables and devices — products that customers must buy again and again rather than one-time purchases, which produces a steady, subscription-like revenue stream. On the vision side, CooperVision designs and manufactures soft contact lenses (daily disposables, two-week and monthly replacement lenses, and specialty lenses for astigmatism/toric, presbyopia/multifocal, and myopia management) that are sold through eye care practitioners, optical retail chains, and online resellers; because lenses are replaced on a fixed schedule, this generates predictable, repeat purchasing once a patient is fit for a given lens. On the women's health side, CooperSurgical sells a broad range of products used in fertility clinics, obstetrics/gynecology practices, and hospitals — including IVF lab consumables and equipment, donor egg/sperm and genetic testing services (following its 2021 acquisition of Generate Life Sciences), surgical instruments and devices for gynecologic procedures, and long-acting reversible contraception (notably the Paragard hormone-free IUD) — earning revenue per procedure, per consumable kit, and per testing/storage service. Both divisions have grown significantly through acquisition (e.g., Ocular Sciences in 2005 expanding CooperVision's lens portfolio, and Cook Medical's reproductive health business in 2022 expanding CooperSurgical's fertility franchise) layered on top of steady organic unit growth.
Business Segments
Cooper reports two operating segments:
- CooperVision — The larger segment, generating roughly $2.8 billion of trailing revenue (about two-thirds of company sales), split between "Toric and Multifocal" specialty lenses (~$1.4 billion, the faster-growing, higher-margin category) and "Sphere and Other" standard lenses (~$1.4 billion). CooperVision is one of the top global contact lens makers by volume, with a broad daily-disposable and myopia-management lens lineup (including its MiSight myopia-control lens for children).
- CooperSurgical — The smaller but faster-growing segment, contributing roughly $1.4 billion of trailing revenue, split between "Office and Surgical Products" (~$0.8 billion — GYN surgical devices, IUDs including Paragard, and related instruments) and "Fertility" (~$0.5 billion — IVF consumables, cryostorage, donor gamete/genetic testing services, and lab equipment). CooperSurgical has been Cooper's primary growth engine via M&A over the past several years as global demand for fertility treatment has expanded.
Competitors
- In contact lenses: Johnson & Johnson Vision (Acuvue), Alcon (Novartis spin-off, Air Optix/Precision1/Total30), Bausch + Lomb, and a number of smaller regional and specialty lens makers — together these four companies (J&J, Alcon, Cooper, Bausch + Lomb) control the large majority of the global soft contact lens market.
- In fertility/women's health: Merck KGaA (fertility drugs and devices), Vitrolife, Hologic (women's health devices/diagnostics), Organon, and various smaller fertility-clinic consumables and genetic-testing companies; Paragard also competes against hormonal IUDs and other contraceptive methods from Bayer and others.
Competitive Position
Cooper's moat rests on scale in a consolidated, oligopolistic contact lens industry with high switching costs (patients are fit to and prescribed a specific lens by their eye doctor, and both patients and practitioners tend to be sticky once established), regulatory barriers to entry (contact lenses are FDA-regulated Class II/III medical devices requiring manufacturing approval and clinical evidence), and manufacturing scale economies that are difficult for new entrants to match. Its specialty lens categories — toric (astigmatism), multifocal (presbyopia), and myopia management for children — are structurally faster-growing and higher-margin than standard spherical lenses, and Cooper has positioned itself as a share leader in several of these categories, notably pediatric myopia control, a category with long growth runway given rising global myopia prevalence. In CooperSurgical, the company has built a leading position in IVF/fertility consumables and services at a time of secular growth in assisted reproduction demand, plus a durable, largely irreplaceable franchise in Paragard, the only FDA-approved non-hormonal IUD in the U.S. Key risks include: intensifying price competition and daily-disposable commoditization in parts of the contact lens market; reimbursement, regulatory, and product-liability risk around Paragard (which has faced product-liability litigation) and other devices; integration risk from Cooper's active M&A strategy in CooperSurgical; foreign-exchange exposure given substantial international sales (softness in Asia-Pacific markets has been cited in recent results); and the general medtech risk of capital-intensive manufacturing combined with dependence on continued innovation to defend premium specialty-lens pricing.